Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States

被引:36
作者
Bhatia, Harpreet S. [1 ]
Hurst, Samantha [2 ]
Desai, Paresh [3 ]
Zhu, Wenhong [3 ]
Yeang, Calvin [1 ]
机构
[1] Univ Calif San Diego, Div Cardiol, Dept Med, La Jolla, CA USA
[2] Univ Calif San Diego, Herbert Wertheim Sch Publ Hlth & Human Longev Sci, La Jolla, CA USA
[3] Univ Calif San Diego, Altman Clin & Translat Res Inst, La Jolla, CA USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2023年 / 12卷 / 18期
基金
美国国家卫生研究院;
关键词
lipoprotein(a); prevention; risk factors; testing; ELEVATED LIPOPROTEIN(A); CARDIOVASCULAR-DISEASE; RISK; DYSLIPIDEMIA; PREVENTION; PREVALENCE; MANAGEMENT; LP(A);
D O I
10.1161/JAHA.123.031255
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite its high prevalence and clinical significance, clinical measurement of lipoprotein(a) is rare but has not been systematically quantified. We assessed the prevalence of lipoprotein(a) testing overall, in those with various cardiovascular disease (CVD) conditions and in those undergoing cardiac testing across 6 academic medical centers associated with the University of California, in total and by year from 2012 to 2021. Methods and Results: In this observational study, data from the University of California Health Data Warehouse on the number of individuals with unique lipoprotein(a) testing, unique CVD diagnoses (using International Classification of Diseases, Tenth Revision [ICD-10], codes), and other unique cardiac testing were collected. The proportion of total individuals, the proportion of individuals with a given CVD diagnosis, and the proportion of individuals with a given cardiac test and lipoprotein(a) testing any time during the study period were calculated. From 2012 to 2021, there were 5553654 unique adults evaluated in the University of California health system, of whom 18972 (0.3%) had lipoprotein(a) testing. In general, those with lipoprotein(a) testing were more likely to be older, men, and White race, with a greater burden of CVD. Lipoprotein(a) testing was performed in 6469 individuals with ischemic heart disease (2.9%), 836 with aortic stenosis (3.1%), 4623 with family history of CVD (3.3%), 1202 with stroke (1.7%), and 612 with coronary artery calcification (6.1%). For most conditions, the prevalence of testing in the same year as the diagnosis of CVD was relatively stable, with a small upward trend over time. Lipoprotein(a) testing was performed in 10753 individuals (1.8%) who had lipid panels, with higher rates with more specialized testing, including coronary computed tomography angiography (6.8%) and apolipoprotein B (63.0%). Conclusions: Lipoprotein(a) testing persists at low rates, even among those with diagnosed CVD, and remained relatively stable over the study period.
引用
收藏
页数:13
相关论文
共 19 条
  • [1] Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US
    Alexander, G. Caleb
    Tajanlangit, Matthew
    Heyward, James
    Mansour, Omar
    Qato, Dima M.
    Stafford, Randall S.
    [J]. JAMA NETWORK OPEN, 2020, 3 (10)
  • [2] Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis
    Bhatia, Harpreet S.
    Ma, Gary S.
    Taleb, Adam
    Wilkinson, Michael
    Kahn, Andrew M.
    Cotter, Bruno
    Yeang, Calvin
    DeMaria, Anthony N.
    Patel, Mitul P.
    Mahmud, Ehtisham
    Reeves, Ryan R.
    Tsimikas, Sotirios
    [J]. ATHEROSCLEROSIS, 2022, 349 : 144 - 150
  • [3] Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
    Bittner, Vera A.
    Szarek, Michael
    Aylward, Philip E.
    Bhatt, Deepak L.
    Diaz, Rafael
    Edelberg, Jay M.
    Fras, Zlatko
    Goodman, Shaun G.
    Halvorsen, Sigrun
    Hanotin, Corinne
    Harrington, Robert A.
    Jukema, J. Wouter
    Loizeau, Virginie
    Moriarty, Patrick M.
    Moryusef, Angele
    Pordy, Robert
    Roe, Matthew T.
    Sinnaeve, Peter
    Tsimikas, Sotirios
    Vogel, Robert
    White, Harvey D.
    Zahger, Doron
    Zeiher, Andreas M.
    Steg, Gabriel
    Schwartz, Gregory G.
    Aylward, Philip E.
    Drexel, Heinz
    Sinnaeve, Peter
    Dilic, Mirza
    Lopes, Renato D.
    Gotcheva, Nina N.
    Prieto, Juan-Carlos
    Yong, Huo
    Lopez-Jaramillo, Patricio
    Pecin, Ivan
    Reiner, Zeljko
    Ostadal, Petr
    Poulsen, Steen Hvitfeldt
    Viigimaa, Margus
    Nieminen, Markku S.
    Danchin, Nicolas
    Chumburidze, Vakhtang
    Marx, Nikolaus
    Liberopoulos, Evangelos
    Montenegro Valdovinos, Pablo Carlos
    Tse, Hung-Fat
    Kiss, Robert Gabor
    Xavier, Denis
    Zahger, Doron
    Valgimigli, Marco
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (02) : 133 - 144
  • [4] Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease
    Colantonio, Lisandro D.
    Bittner, Vera
    Safford, Monika M.
    Marcovina, Santica
    Brown, Todd M.
    Jackson, Elizabeth A.
    Li, Mei
    Lopez, J. Antonio G.
    Monda, Keri L.
    Plante, Timothy B.
    Kent, Shia T.
    Muntner, Paul
    Rosenson, Robert S.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (11):
  • [5] 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
    Grundy, Scott M.
    Stone, Neil J.
    Bailey, Alison L.
    Beam, Craig
    Birtcher, Kim K.
    Blumenthal, Roger S.
    Braun, Lynne T.
    de Ferranti, Sarah
    Faiella-Tommasino, Joseph
    Forman, Daniel E.
    Goldberg, Ronald
    Heidenreich, Paul A.
    Hlatky, Mark A.
    Jones, Daniel W.
    Lloyd-Jones, Donald
    Lopez-Pajares, Nuria
    Ndumele, Chiadi E.
    Orringer, Carl E.
    Peralta, Carmen A.
    Saseen, Joseph J.
    Smith, Sidney C., Jr.
    Sperling, Laurence
    Virani, Salim S.
    Yeboah, Joseph
    [J]. CIRCULATION, 2019, 139 (25) : E1082 - E1143
  • [6] CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE ALGORITHM-2020 EXECUTIVE SUMMARY
    Handelsman, Yehuda
    Jellinger, Paul S.
    Guerin, Chris K.
    Bloomgarden, Zachary T.
    Brinton, Eliot A.
    Budoff, Matthew J.
    Davidson, Michael H.
    Einhorn, Daniel
    Fazio, Sergio
    Fonseca, Vivian A.
    Garber, Alan J.
    Grunberger, George
    Krauss, Ronald M.
    Mechanick, Jeffrey, I
    Rosenblit, Paul D.
    Smith, Donald A.
    Wyne, Kathleen L.
    [J]. ENDOCRINE PRACTICE, 2020, 26 (10) : 1196 - 1224
  • [7] Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population
    Kamstrup, Pia R.
    Nordestgaard, Borge G.
    [J]. JACC-HEART FAILURE, 2016, 4 (01) : 78 - 87
  • [8] Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
    Kronenberg, Florian
    Mora, Samia
    Stroes, Erik S. G.
    Ference, Brian A.
    Arsenault, Benoit J.
    Berglund, Lars
    Dweck, Marc R.
    Koschinsky, Marlys
    Lambert, Gilles
    Mach, Francois
    McNeal, Catherine J.
    Moriarty, Patrick M.
    Natarajan, Pradeep
    Nordestgaard, Borge G.
    Parhofer, Klaus G.
    Virani, Salim S.
    von Eckardstein, Arnold
    Watts, Gerald F.
    Stock, Jane K.
    Ray, Kausik K.
    Tokgozoglu, Lale S.
    Catapano, Alberico L.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 (39) : 3925 - 3946
  • [9] Elevated Lipoprotein(a) and Risk of Ischemic Stroke
    Langsted, Anne
    Nordestgaard, Borge G.
    Kamstrup, Pia R.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (01) : 54 - 66
  • [10] Mach F, 2020, EUR HEART J, V41, P111, DOI [10.1093/eurheartj/ehz455, 10.15829/1560-4071-2020-3826]